Thermo Fisher Scientific (TMO) is expected to report Q4 earnings with a conference call scheduled for 9:00 am ET Wednesday.
Analysts are looking for a profit of 69c on revenue of $2.51B. The consensus is 67c to 71c for EPS, and revenue of $2.5B to $2.51B, according to First Call. In October, the company raised its 2007 EPS guidance to $2.56 to $2.59 from $2.50 to $2.56 vs. First Call consensus of $2.59, and revenue to $9.6B to $9.65B from $9.5B to $9.55B vs. consensus of $9.63B. Thermo Fisher's CEO said India and China offer enormous growth opportunities, and that revenue from China will double over the next five years.
Thomas Weisel said that life science companies who increase international exposure, and with strong balance sheets, will be better able to weather a recession. The firm rates Thermo Fisher a top pick due to its recurring revenues and high growth diagnostic markets. Leerink Swann said attractive sales growth can begin to be generated at the end of the year, and anticipates additional operating margin expansion from integrating acquired assets and leveraged infrastructure.
Next event: The company will participate in the Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7.